One such example is epratuzumab, an anti‐CD22 antibody which triggers inhibition of BCR mediated signaling and was tested in clinical trials for the autoimmune disease SLE (Leonard & Goldenberg, 2007; Wallace et al, 2014; Özgör et al, 2016). Here, CD22 is linked to systemic lupus erythematosus.